AR and breast carcinoma: In AR+/ER− breast cancer, AR is a biomarker of radioresistance and inhibition or knockdown of AR results in radiosensitisation, partially through the inhibition of a non-homologous end-joining (NHEJ) repair-mediated response [7, 8].